Further signs Australia's GDP is set to slump
While the drag was modest, Australia's current account balance rose by $1.7bn for the first three months of 2025 to an overall deficit of $14.7bn.
This was larger than a forecast estimate of $12.5bn.
Oxford Economics Australia lead economist Ben Udy said Tuesday's current account balance released by the Australian Bureau of Statistics was just another sign of a slowing economy.
'The modest drag from net trade along with recent downbeat GDP particles paints a sombre picture for tomorrow's GDP reading,' he said.
The decline in the current account balance was largely driven by a fall in the Australian dollar, as net primary income lifted in Q1.
The trade balance changed little in the quarter, as a small improvement in the balance of goods was offset by a $0.2bn fall in the goods and services surplus.
ABS head of international statistics Tom Lay said there was mixed news for commodities.
'Commodity price falls, notably coal, led to Australian mining businesses seeing lower profits flow to foreign direct investors, which reduced Australia's income outflows,' he said.
But the price of gold rose sharply in the first three months, leading to exports of goods to lift by 2.9 per cent following a 2.3 per cent rise in the last quarter.
This was the first consecutive growth in exports since the June 2022 quarter.
The March rise was led by non-monetary gold, with more gold being exported and prices continuing to rise from previous highs in the December 2024 quarter.
'The $4.8bn rise in non-monetary gold exports was the highest on record. It was led by $11bn of non-monetary gold exports to the USA, which was larger than the total combined value of non-monetary gold exports to the USA over the past four years,' Mr Lay said.
Without the gold contribution, goods exports would have fallen by 1 per cent in the March quarter.
Separate business indicator data also released by the ABS painted a similar picture with company gross operating profits falling 0.5 per cent for the March quarter on the back of a weaker mining sector.
Company gross operating profits also fell by 6 per cent.
The current account balance also showed exports of services fell 1.7 per cent this quarter, with a 2.8 per cent fall in travel services.
Education-related travel exports also declined in the March quarter.
'Cost-of-living pressures and global uncertainty still appear to be weighing on households' travel plans, with both exports and imports of travel services declining in the quarter,' Mr Udy said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
2 minutes ago
- News.com.au
New signing Jaiden Kucharski and captain Ben Garuccio unable to play for Western United due to FIFA registration ban
Western United could lose recent signing Jaiden Kucharski before he plays a competitive game for the club due to a registration ban that will prevent him and club captain Ben Garuccio from playing in an Australia Cup round-of-32 clash against Sydney FC on Tuesday night. United announced the signing of ex-Sky Blues attacker Kucharski earlier this month despite knowing that he could not be registered due to an ongoing FIFA ban stemming from a unresolved financial dispute involving the club's former striker Aleksandar Prijovic. The ban also applies to left-back Garuccio, as he didn't re-sign with United until after he had become a free agent, meaning he needs to be re-registered. As a result, the pair can't play against the Sydneysiders at Ironbark Fields, and Football Australia is also investigating whether United breached the ban by fielding Kucharski in a friendly game last week against NPL Victoria club Oakleigh Cannons. It continues the turmoil that the financially embattled United finds itself in. The club's proposed new ownership structure, which was announced in May and involves KAM Melbourne, a subsidiary of American company KAM Sports buying a $100m controlling stake in the club and its parent company Western Melbourne Group, is yet to be approved by the Australian Professional Leagues, which runs the A-League. The lengthy delay for approval is understood to be because the APL is yet to receive KAM Melbourne's completed ownership proposal. The ongoing uncertainty about United's future, as well as its inability to play, has 23-year-old Kucharski and his representatives assessing his immediate future. Other A-League clubs are interested in the services of the former Australian under-17 international, and there are suggestions he might seek to be released from his two-year contract unless the registration ban is resolved, and that could be dependent on KAM Melbourne's majority ownership of United being approved. United's financial problems meant players and staff were paid late for three successive months until this month's wages arrived on time. Superannuation payments were due on Monday. United will face a Sydney side that won't include Brazilian star Douglas Costa, who is yet to arrive back in Australia following an extended off-season break. Sydney's bid to sign former Bayern Munich star Thomas Muller has failed, with the German veteran electing to continue his career in America's Major League Soccer competition, most likely with Canada-based club Vancouver Whitecaps. In other Australia Cup round-of-32 games on Tuesday night, Gold Coast Knights host Auckland FC, Southern Districts Raiders meet Macarthur FC, and Olympic Kingsway take on Melbourne Victory. In Sunday's all A-League battle, Wellington Phoenix knocked Perth Glory out of the Cup, winning a penalty shootout 8-7 after scores were locked at 1-1 at the end of normal time and extra time.
ABC News
2 minutes ago
- ABC News
What influencers and content creators can claim as tax deductions
When Queenie Tan started earning income as a content creator, she was a bit "scrappy" with her record keeping. "I wasn't earning very much, it was just on the side," the 29-year-old licensed financial creator from Sydney/Gadigal Country says. "My first purchase was a $50 microphone — I would forget to keep receipts for those sorts of things, but you should, because that could be deducted." Jenny Wong, tax lead in policy and advocacy at Australia's largest accounting body CPA Australia, says influencers may not be aware of what they can claim on tax, as well as what they need to declare. For example, non-cash benefits such as gifts. Ms Wong says income generated from side-hustles has become a major focus for the Australian Taxation Office (ATO), with digital service platforms such as YouTube and OnlyFans now legally required to report the income earned by their users. "[Sometimes content creators] think it's a hobby and they don't need to declare … but if there is some regular activity or potential of making profit, then in most cases, generally the ATO will see that as income." The tax implications of earning money from content creation, including content created as an influencer on social media platforms, is "the same as for anyone else", an ATO spokesperson says. "Income earned is taxable, regardless of the form in which it is given to you." If you are paid with goods or other benefits, for example being able to keep an outfit used in a post, or being "gifted" something, that is classed as a "bartering transaction". And that is subject to the same income tax and GST treatment as normal cash or credit payments, the spokesperson says. If an influencer is earning money through continuous and repeated activities for the purpose of making a profit, then it's likely they are running a business, according to the ATO. "If so, they will need to register for GST and lodge a business activity statement if they exceed or expected to meet the GST turnover threshold of $75,000 per annum," the spokesperson says. Influencing would not be considered a business if it was a one-off transaction, or a hobby, or recreation in which you don't seek to profit, for example. Queenie, who has 450,000 followers across her social platforms, is now a full-time content creator. And she has become much better at knowing what she can claim. Because she makes video content, Queenie has claimed camera equipment, microphones and lighting equipment on her tax. The ATO says to be able to claim a deduction for an expense you must spend the money yourself and not get a reimbursement, the expense must directly relate to earning your income, and you must have a record to prove it (usually a receipt). "You can only claim GST credits for the GST included in the price of any goods and services acquired for business purposes," a spokesperson says. Queenie says she stays on top of her tax by keeping things separate to her everyday spending. "Now I use [an app] which just makes it so much easier. It connects to all your bank accounts, and now I have a separate credit card just for business purposes." The ATO spokesperson says it is important to maintain accurate records. "We have sophisticated data-matching and analytical tools that enable us to identify under-reporting of income or not being registered for GST when required to be. "Where we identify people that have made a genuine mistake, we will support them in understanding the law and getting back on track." If in doubt, Ms Wong recommends people see a registered tax accountant. "Don't risk it." This article contains general information only. You should consider obtaining independent professional advice in relation to your particular circumstances.
News.com.au
29 minutes ago
- News.com.au
Health Check: Clarity shares surge after ‘fast and sizeable' $203m raise
• Clarity Pharmaceuticals rocket up to 12% after its blitzkrieg placement • Artrya, Botanix and Imricor are among today's quarterly updates • Lumos outlines US market potential Radiopharmaceutical group Clarity Pharmaceuticals (ASX:CU6) has surprised investors with a monstrous $203 million institutional placement, struck at a 15% premium to the company's 15-day average price. None will be more surprised than the short sellers, who account for close to 10% of the company's register. Executive chairman Dr Alan Taylor says the 'fast, well executed and sizeable' placement was to a small group of local instos 'close to the company'. Unusually, no-one blabbed and the shares did not enter trading halt. 'I have never done a deal that fast,' Taylor told Stockhead. 'A week ago, I would have said we were not doing a capital raising, but there was a lot of interest from a very concentrated group . "The raising was struck at $4.20 a share, a 2.2% premium to Friday's close and a hefty 18% more than the 15-day weighted average price. The raising comes amid what Taylor dubs 'an incredibly tumultuous' period driven by US politics, as well as some 'unfortunate news' from local biotechs (read: Opthea's (ASX:OPT) phase III trial failure). In December Clarity shares were promoted to the ASX200, which was good for enhancing Clarity's profile. But it also contributed to shorting activity. Given the share gains, these investors are likely to be buying up stock to cover their positions. Well funded for trials Clarity emerges from the raising with $288 million of cash, which will fund the company's packed slate of trials. These include two phase III prostate cancer imaging trial aimed at US Food & Drug Administration registration, dubbed Amplify and Clarify. Amplify is for patients with biochemical recurrence post treatment; Clarify is for those intended to undertake prostate removal. Both are open label and single-arm (with no placebo and comparison cohort). Another trial on the sidelines, Co-PSMA compares Clarity's tool with the standard-of-care diagnosis methods. The company expects an initial data readout on this one before the end of the year, with Amplify and Clarify readouts next year. Clarity listed in August 2021, raising a record $92 million at $1.40 apiece. The company then went one better in April last year, raising $121 million in a right issue and placement (at $2.55 a share). The raising is one of the biggest in biotech history and the chunkiest since Mesoblast gathered $260 million in a placement in January. Imricor confident of US approval Imricor Medical Systems (ASX:IMR) is confident of US approval of its world-first ablation catheter this year. We say 'world's first' because the device is the only one capable of being guided by magnetic resonance imaging (MRI), as opposed to x-ray fluoroscopy. Imricor's submission is by way of a staggered, modular process. The company reports the second module is under review and the company expects to submit the third module in the December quarter. 'We expect a steady string of 510(k) product submissions and approvals , which in turn helps accelerate the commercial launch across the US," the company says. In the March quarter European regulators approved Vision-MR, the company's updated catheter for type 1 atrial flutter, under the Continent's bolstered Medical Devices Regulation. In the June quarter they also gave the nod to Advantage-MR, which enables a physician to use a recording system and cardiac stimulator while ablating. The European gatekeepers also approved Northstar, 'the world's only MRI-native 3D mapping and guidance system.' With June quarter receipts of US$85,000, Imricor is yet to start European sales in earnest. The company posted June quarter outflows of US$4.43 million, taking cash on hand to a handy US$50.3 million. Sales will flow this quarter, says plaque-buster Artrya Still on matters of the heart, Artrya (ASX:AYA) expects first US subscription revenue from its AI-enabled Salix coronary plaque detection platform in the current quarter. An algorithm-based artificial intelligence tool, Salix detects the plaque deposits on x-ray coronary computed tomography angiograph (CCTA) images. Despite vulnerable plaque being the cause of most heart attacks, plaque currently is not routinely reported in cardiac imaging and diagnostics. It's difficult to detect with the naked eye in traditional images. In March the FDA approved Salix Coronary Anatomy (SCA) and Artrya is now seeking the agency's consent for Salix Coronary Plaque (SCP). SCP expands applicability to detecting and quantifying coronary arterial plaque for those patients who have undergone a coronary CT angiogram. The SCP module will integrate automatically with SCA. SCA already is being trialled and in clinical use, by Artrya's customers and partners, generating a symbolic $8000 in receipts of the quarter. Earlier this month Artrya inked its first commercial deal, a five-year minimum $600,000 contract with Tanner Health. Artrya expended $5.44 million for the quarter, taking cash to $11.3 million. The company expects a $4.5-5 million R&D tax refund by the end of the year. Botanix reports 600% revenue uptick Botanix Pharmaceuticals (ASX:BOT) reports net revenue of $4.3 million from US sales of Sofdra, compared with $700,000 in the March quarter. The company launched the drug – which treat an excessive sweating condition – in the US in March quarter. The 'net' descriptor is relevant, because some folks were taken aback after the company's July 8 update which showed the extent to which other parties clipped the revenue ticket, Doctors wrote 7053 prescriptions during the quarter, 324% higher than 2975 in the March stanza. The number of prescribers rose 11%, to 2316 from 1075 previously. Launching a drug is not cheap and the company burnt $28.4 million, leaving cash of $64.9 million. Let's be CLIA, it's a big market says Lumos Lumos Diagnostics (ASX:LDX) expects its Febridx virus-versus-bacterial diagnostic tool to capture eight million US patients within three years, via its company making distribution deal with Phase Scientific. Announcing the tie up on July 16, Lumos said the deal would deliver US$2 million immediately – cash the company has, indeed, banked – and a total of US$317 million ($487 million) over six years. Detailing the arrangement on Friday, CEO Doug Ward said the company expected a total addressable market of 80 million, assuming the FDA grants a so-called CLIA waiver. The number consists of patients present with acute respiratory infections. 'Our thinking is that in years two to three we will be 2% or 3% of that,' Ward said. 'In year six, that ramps up to 10%.' As in Clinical Laboratories Improvement Act, CLIA requires hospitals and labs to operate under government accreditation Exemption from CLIA enables parties such as GPs and medical assistants to carry out the low-complexity lateral-flow assays. In financial terms, the market increases tenfold, to US$1 billion a year. Lumos is carrying out a trial to support its FDA application and has recruited close to 120 of the bacterial-positive patients required. Coming back to the finances, Phase pays Lumos another US$1.5 million on its CLIA application, expected next month. On FDA approval, Phase pays another US$5 million. That leaves US$308 million over years three to six, which Ward says is based on minimum order volumes. Lumos shares rocketed 133% on the back of the Phase announcement and have held their gains.
